<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">
  <meta name="viewport" content="width=device-width, initial-scale=1">
  <title>Metoclopramide - Medications - Offline Clinical Reference</title>
  <link rel="stylesheet" href="../style.css">
</head>
<body>
  <div class="topbar">
    <div class="topbar-inner">
      <span class="pill"><strong>Metoclopramide</strong></span>
      <span class="spacer"></span>
      <div class="nav-btns">
        <a class="btn small" href="../index.html">Home</a>
        <a class="btn small" href="../medications.html">Back to Medications</a>
      </div>
    </div>
  </div>

  <main class="wrap">
    <section class="section">
      <div class="kicker">GI</div>
      <h1>Metoclopramide</h1>

      <div class="content">
        <h3>Stocked on board</h3>
        <ul>
          <li>Metoclopramide 5mg/mL Injection 2mL</li>
        </ul>

        <div class="rule"></div>

        <h3>Adult dosing</h3>
        <ul>
          <li><strong>Nausea/vomiting (including migraine-associated nausea; protocol-dependent)</strong>
            <ul>
              <li>0.1 mg/kg IV/IM/IO to a maximum single dose of 10 mg</li>
              <li>May repeat every 6 hours as required</li>
              <li>Total daily dose limit: 0.5 mg/kg/day (per protocol guidance)</li>
            </ul>
          </li>
          <li><strong>Renal impairment</strong>
            <ul>
              <li>If renal impairment is known/suspected and ongoing dosing is needed: consider dose reduction and follow local guidance/medical direction</li>
            </ul>
          </li>
        </ul>

        <div class="rule"></div>

        <h3>Indications</h3>
        <ul>
          <li>Symptomatic treatment of nausea and vomiting (including migraine-associated nausea)</li>
          <li>Prokinetic effect may be useful when delayed gastric emptying is suspected (context dependent)</li>
        </ul>

        <div class="rule"></div>

        <h3>Contraindications / cautions</h3>
        <ul>
          <li>Hypersensitivity to metoclopramide</li>
          <li>Suspected/known bowel obstruction or perforation, or GI bleeding (do not use)</li>
          <li>Seizure disorder (may lower threshold)</li>
          <li>Parkinsonism / history of extrapyramidal reactions or dystonia</li>
          <li>MAOI use within the past 14 days (avoid)</li>
          <li>Caution with QT-prolongation risk and in older adults (CNS effects/extrapyramidal risk)</li>
        </ul>

        <div class="rule"></div>

        <h3>Adverse effects</h3>
        <ul>
          <li>Akathisia/restlessness, anxiety</li>
          <li>Acute dystonic reaction / other extrapyramidal symptoms (can be abrupt)</li>
          <li>Drowsiness, fatigue</li>
          <li>Diarrhea</li>
          <li>Rare/serious: QT prolongation/arrhythmia risk (patient/context dependent); tardive dyskinesia with prolonged/repeated use</li>
        </ul>

        <div class="rule"></div>

        <h3>Preparation &amp; administration</h3>
        <ul>
          <li>Supplied: 5 mg/mL in 2 mL vial (10 mg total)</li>
          <li>IV/IM/IO: administer per local protocol; give IV doses slowly to reduce restlessness/adverse effects</li>
          <li>If acute dystonia occurs: treat per local protocol (diphenhydramine is commonly used)</li>
        </ul>

        <div class="rule"></div>

        <h3>Monitoring</h3>
        <ul>
          <li>Symptom response (nausea/vomiting control; ability to hydrate/retain PO)</li>
          <li>Observe for akathisia/dystonia/extrapyramidal symptoms after dosing</li>
          <li>Level of alertness/sedation</li>
          <li>If cardiac risk factors present: consider ECG/QT context per local practice</li>
        </ul>

        <div class="rule"></div>

        <h3>At-sea considerations</h3>
        <ul>
          <li>Have a plan for managing extrapyramidal reactions (recognize early; treat per protocol)</li>
          <li>If patient needs to remain operational, consider sedation/akathisia impacts before dosing</li>
          <li>Document dose/time carefully; avoid repeated dosing without reassessment</li>
        </ul>

        <div class="rule"></div>

        <h3>Online-only references</h3>
        <ul>
          <li>Documentation: BCEHS drug monograph (adult dosing/contraindications)</li>
          <li>Documentation: Example Canadian product monograph (metoclopramide injection)</li>
        </ul>
      </div>

      <p class="foot">
        Verify dosing and indications against current clinical guidelines.
      </p>
    </section>
  </main>
</body>
</html>
